EUCTR2012-000478-42-GB进行中（未招募）不适用
EPTUNE: A Randomised Phase II Study of Neoadjuvant TAK-700 and Leuprorelin Acetate versus Surgery Alone in Intermediate and High Risk Clinically Localized Prostate Cancer - NEPTUNE
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 136
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1.Willing and able to provide written informed consent
- •2.No previous treatment for prostate cancer (including surgery, any hormone therapy, radiotherapy, cryotherapy).
- •3.Age = 18 years and male
- •4.Histologically or cytologically confirmed adenocarcinoma of the prostate with Gleason score.
- •5. A prostate biopsy within 8 weeks from screening is allowed for entry requirements.
- •6.Intermediate or high risk prostate cancer according to National Comprehensive Cancer Network (NCCN) risk stratification criteria:
- •Intermediate: PSA >10 & <20 or a Gleason score 7 or clinical stage up to and
- •including T2c disease.
- •High risk: PSA>20 or Gleason 8-10 or clinical stage >T2c
- •7.Serum testosterone > 200 ng/dL
- •8.Prostatectomy is the planned treatment option.
- •9.Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- •10.Adequate organ function, defined as follows:
- •Haemoglobin >10.0g/dL
- •Absolute neutrophil count > 1.5 x 109/L
- •Platelet count >100 x 109/L
- •AST and /or ALT <2.5 x ULN
- •Total Bilirubin <1.5 x ULN
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 45
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 91
排除标准
- •1.Serious co-existent medical conditions, such as chronic active autoimmune disease, (within the last 6 months) or infection (such as hepatitis).
- •2.Uncontrolled hypertension within the screening period (systolic BP = 160 mmHg or diastolic BP = 95 mmHg). Patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive therapy.
- •3.Patients taking regular oral steroids for any reason.
- •4.Previously treated prostate cancer (including radiotherapy, hormone therapy or surgery).
- •5.History of pituitary or adrenal dysfunction
- •6.Other active malignancy over the last 5 years that has required systemic therapy excluding:
- •a. Adjuvant therapy in the curative setting
- •b. Non-melanoma skin cancer
- •c.Superficial transitional cell carcinoma (CIS-T1).
- •7.History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug
- •8.Current enrolment in an investigational drug or device study or participation in such a study within 30 days of Day 1
- •9.Not willing to comply with the procedural requirements of this protocol.
- •10.Patients who have partners of childbearing potential who are not willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 16 weeks after last study drug administration.
- •11.Uncontrolled diabetes mellitus, in the opinion of the treating physician.
- •12.Known hypersensitivity to compounds related to TAK-700 or to TAK-700 excipients.
- •13.Hypersensitivity to any of the ingredients or to synthetic Gn-RH or Gn-RH derivatives.
- •14.Screening calculated ejection fraction of = 50% by echocardiogram.
- •15.History of myocardial infarction, unstable symptomatic ischemic heart disease, ongoing arrhythmias of Grade > 2 (NCI CTCAE, version 4.02), thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (e.g., pericardial effusion restrictive cardiomyopathy) within 6 months prior to first dose of study drug. Chronic stable atrial fibrillation on stable anticoagulant therapy is allowed.
- •16.New York Heart Association Class III or IV heart failure
- •17.ECG abnormalities of Q-wave infarction, unless identified 6 or more months prior to screening
- •18.QTc interval > 460 msec on ECG
研究者
相似试验
进行中（未招募）
1 期
A Randomized Phase-2 Trial to Evaluate the Effects of the IRX-2 Regimen before Surgery and after Chemotherapy or Radiation in Newly Diagnosed Patients with Stage II, III or IVA Squamous Cell Cancer of the Oral Cavityewly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity.MedDRA version: 19.0Level: PTClassification code 10041857Term: Squamous cell carcinoma of the oral cavitySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-000373-21-ESIRX Therapeutics, Inc.200
进行中（未招募）
1 期
A Randomized Phase-2 Trial to Evaluate the Effects of the IRX-2 Regimen before Surgery and after Chemotherapy or Radiation in Newly Diagnosed Patients with Stage II, III or IVA Squamous Cell Cancer of the Oral Cavityewly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity.MedDRA version: 20.0Level: PTClassification code 10041857Term: Squamous cell carcinoma of the oral cavitySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-000373-21-HUIRX Therapeutics, Inc.200
进行中（未招募）
1 期
A Randomized Phase-2 Trial to Evaluate the Effects of the IRX-2 Regimen before Surgery and after Chemotherapy or Radiation in Newly Diagnosed Patients with Stage II, III or IVA Squamous Cell Cancer of the Oral Cavityewly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of theOral Cavity.MedDRA version: 20.0Level: PTClassification code 10041857Term: Squamous cell carcinoma of the oral cavitySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-000373-21-ITIRX THERAPEUTICS, INC.200
进行中（未招募）
1 期
Randomized Controlled Trial comparing two groups of Patients with High-Risk, Localized Soft Tissue Sarcoma of the Extremity: the first one receiving Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab after surgery, and the second one receiving Radiotherapy and surgery, aiming to assess the safety and efficacy profile of PembrolizumabThis trial investigates whether neoadjuvant radiotherapy combined with pembrolizumab followed by surgical resection and adjuvant pembrolizumab improves disease-free survival for patients with high-risk soft tissue sarcoma of the extremity (undifferentiated pleomorphic sarcoma or dedifferentiated/pleomorphic liposarcoma, tumor size > 5 cm, grade 2 or 3 out of 3) compared to radiotherapy alone followed by surgical resectionMedDRA version: 20.0Level: PTClassification code 10024629Term: Liposarcoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10041298Term: Soft tissue sarcomas histology unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001360-39-ITSARC110
进行中（未招募）
1 期
eoadjuvant Lu-PSMA radioligand therapy and Ipilimumab in men with very high-risk prostate cancer (NEPI)Patients with very high-risk prostate cancer (as defined by a total Gleason-Score =4+4 [ISUP-GG 4+5] and clinical stage cT3 (digital rectal examinations or imaging based) plus clinical nodal status cN+ or Serum-PSA level > 20 ng/ml who are candidates for radical prostatectomy with pelvic lymph node dissection.CTIS2024-514386-19-00niversitaetsklinikum Essen AöR58